Bone marrow histomorphology and JAK2 mutation status in essential thrombocythemia

APMIS

Volumn 115, Issue 11, 2007, Pages 1267-1273

  Larsen, Thomas Stauffer ^a   Hasselbalch, Hans Carl ^a   Pallisgaard, Niels ^a   Møller, Michael Boe ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Essential thrombocythemia; Idiopathic myelofibrosis; JAK2; Prefibrotic; qPCR

Indexed keywords

HEMOGLOBIN; JANUS KINASE 2;

ARTICLE; BONE MARROW; BONE MARROW BIOPSY; CONTROLLED STUDY; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SCORING SYSTEM; THROMBOCYTE; THROMBOCYTHEMIA;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; BIOPSY; BONE MARROW; ERYTHROPOIESIS; FIBROSIS; GRANULOCYTES; HEMOGLOBINS; HUMANS; JANUS KINASE 2; MACROPHAGES; MEGAKARYOCYTES; MIDDLE AGED; MUTATION; PLATELET COUNT; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; STROMAL CELLS; THROMBOCYTHEMIA, HEMORRHAGIC;

EID: 37349007275     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0643.2007.00807.x     Document Type: Article

References (23)

1. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005 434 : 1144 8.
2. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005 365 : 1054 61.
3. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005 352 : 1779 90.
4. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005 7 : 387 97.
5. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006 108 : 1652 60.
6. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006 107 : 4274 81.
7. Levine RL, Gilliland DG. JAK-2 mutations and their relevance to myeloproliferative disease. Curr Opin Hematol 2007 14 : 43 7.
8. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006 355 : 2452 66.
9. Thiele J, Kvasnicka HM, Orazi A. Bone marrow histopathology in myeloproliferative disorders - current diagnostic approach. Semin Hematol 2005 42 : 184 95.
10. Vardiman JW. The new World Health Organization classification of myeloid neoplasms: Q&A with James W. Vardiman, MD. Clin Adv Hematol Oncol 2003 1 : 18 21.
11. Michiels JJ, Thiele J. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia). Int J Hematol 2002 76 : 133 45.
12. Thiele J, Kvasnicka HM, Diehl V, Fischer R, Michiels J. Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies. Leuk Lymphoma 1999 33 : 207 18.
13. Thiele J, Kvasnicka HM. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol 2003 82 : 148 52.
14. Florena AM, Tripodo C, Iannitto E, Porcasi R, Ingrao S, Franco V. Value of bone marrow biopsy in the diagnosis of essential thrombocythemia. Haematologica 2004 89 : 911 9.
15. Gianelli U, Vener C, Raviele PR, Moro A, Savi F, Annaloro C, et al. Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology. Leuk Lymphoma 2006 47 : 1774 81.
16. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der WJ, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005 90 : 1128 32.
17. Thiele J, Kvasnicka HM. A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders. Leuk Lymphoma 2006 47 : 381 96.
18. Bousquet M, Le GS, Quelen C, Rigal-Huguet F, Delsol G, Brousset P. Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay. A retrospective study with pathologic correlations. Hum Pathol 2006 37 : 1458 64.
19. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005 366 : 1945 53.
20. Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol 2007 13 : 745 51.
21. Michiels JJ, De Raeve H, Berneman Z, Van Bockstaele D, Hebeda K, Lam K, et al. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders. Semin Thromb Hemost 2006 32 : 307 40.
22. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006 3 : e270.
23. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006 108 : 3472 6.